Figure 2.
Figure 2. Proliferation capacity of thymic stromal cells. (A) Dot plots of MHC II versus Ki67 expression on CD45– thymic stromal cells at various time points, with regions indicating the proportion of Ki67+ TECs (CD45–/MHC II+) and Ki67+ non-TECs (CD45–/MHC II–). Histograms show Ki67 (solid line) and isotype control (dashed line) staining gated on TECs with markers indicating the proportion of Ki67+ TECs. (B) Histograms of Ki67 expression on cTECs (CD45–/MHC II+/Ly51+) and mTECs (CD45–/MHC II+/Ly51–) from 4-week-old mice, with markers set according to isotype controls. (C) MHC II expression versus BrdU incorporated into 4-week-old CD45– stromal cells following 3 days of constant exposure. The proportion of CD45– cells that are BrdU+ TECs is indicated. All plots are representative of 3 experiments performed.

Proliferation capacity of thymic stromal cells. (A) Dot plots of MHC II versus Ki67 expression on CD45 thymic stromal cells at various time points, with regions indicating the proportion of Ki67+ TECs (CD45/MHC II+) and Ki67+ non-TECs (CD45/MHC II). Histograms show Ki67 (solid line) and isotype control (dashed line) staining gated on TECs with markers indicating the proportion of Ki67+ TECs. (B) Histograms of Ki67 expression on cTECs (CD45/MHC II+/Ly51+) and mTECs (CD45/MHC II+/Ly51) from 4-week-old mice, with markers set according to isotype controls. (C) MHC II expression versus BrdU incorporated into 4-week-old CD45 stromal cells following 3 days of constant exposure. The proportion of CD45 cells that are BrdU+ TECs is indicated. All plots are representative of 3 experiments performed.

Close Modal

or Create an Account

Close Modal
Close Modal